Roche stock tumbled Monday — giving way to steeper losses for Olema — after its oral breast cancer treatment failed in ...

Roche ( RHHBF) ( RHHBY) shares fell after the Swiss drugmaker’s investigational breast cancer pill failed to meet the primary goal of a late-stage breast cancer trial.

The results of the clinical trial mark a setback for the Swiss pharmaceutical company, which saw in the drug, giredestrant, a candidate to become a blockbuster treatment.

Roche's shares dropped more than 5% on Monday as the ​Swiss drugmaker failed to show that its promising breast cancer drug ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 7% at one stage on Monday, their biggest decline in nearly a ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

Olema Pharmaceuticals (OLMA) stock plummeted 41% after Roche's Phase 3 breast cancer trial failed its primary endpoint, ...

Investing.com -- Roche Holding (SIX:ROG) announced Monday that an experimental drug combination for breast cancer treatment failed to achieve its primary endpoint in a late-stage clinical trial.

Roche Holding AG shares fell more than 5% on Monday after its experimental breast cancer pill giredestrant failed a pivotal clinical trial, casting doubt on a dru ...

Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate ...